NASDAQ:KTTA Pasithea Therapeutics Q4 2024 Earnings Results & Report $0.42 +0.01 (+1.37%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Pasithea Therapeutics reported Q4 2024 earnings on March 24, 2025. The company reported EPS of -$2.41. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 24, 2025TimeAfter Market Closes Pasithea Therapeutics EPS ResultsActual EPS-$2.41Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APasithea Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPasithea Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Pasithea Therapeutics Q4 2024 Earnings FAQ Did Pasithea Therapeutics beat earnings estimates for Q4 2024? Pasithea Therapeutics (NASDAQ:KTTA) reported earnings of -$2.41 per share for Q4 2024. The report was announced on Monday, March 24, 2025. When is Pasithea Therapeutics' next earnings date? Pasithea Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Pasithea Therapeutics on the company's earnings history page. Pasithea Therapeutics Earnings HeadlinesPasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European ...September 14, 2026 | finance.yahoo.comPasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceSeptember 14, 2026 | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)Pasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesSeptember 3, 2026 | globenewswire.comPasithea Therapeutics Corp KTTAAugust 15, 2026 | morningstar.comMPasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026July 21, 2026 | globenewswire.comSee More Pasithea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email. Email Address About Pasithea TherapeuticsPasithea Therapeutics (NASDAQ:KTTA) is a biotechnology company focused on developing treatments for central nervous system disorders and other serious diseases. The company’s research has included novel pharmaceutical therapies as well as psychedelic- and ketamine-assisted treatment approaches for conditions such as depression and other mental health disorders. Pasithea’s development portfolio has included PAS-004, an orally administered MEK1/2 inhibitor designed to affect the RAS/MAPK signaling pathway. The company has pursued potential applications for this type of therapy in oncology and other diseases involving abnormal cellular signaling, while continuing to evaluate opportunities in neuroscience. Historically, Pasithea also operated or planned ketamine treatment clinics in the United States and the United Kingdom and conducted research involving psychedelic medicines. The company was founded in 2020, with neuroscientist and psychiatrist Dr. Tiago Reis Marques serving as a key member of its founding leadership.View Pasithea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth Path Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
